ODONATE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18,810 USD | +10.00% |
|
+9.22% | +25.40% |
| 2023 | North American Morning Briefing : Recession Threat Grows as Further Tightening Likely | DJ |
| 2023 | North American Morning Briefing : Stock Futures -2- | DJ |
| Sales 2019 | - | Sales 2020 | - | Capitalization | 740M 59.25B |
|---|---|---|---|---|---|
| Net income 2019 | -112M -8.97B | Net income 2020 | -126M -10.09B | EV / Sales 2019 | - |
| Net cash position 2019 | 178M 14.28B | Net cash position 2020 | 152M 12.17B | EV / Sales 2020 | - |
| P/E ratio 2019 * |
-
| P/E ratio 2020 |
-
| Employees | 145 |
| Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +10.00% | ||
| 1 week | +9.22% | ||
| Current month | +7.49% | ||
| 1 month | +10.97% | ||
| 3 months | +14.00% | ||
| 6 months | +25.40% | ||
| Current year | +25.40% |
1 week
17 100.00
18 810.00
1 month
15 400.0018 810.00
Current year
13 625.0049 895.00
1 year
13 625.0049 895.00
3 years
8 077.0049 895.00
5 years
8 077.00464 999.00
10 years
8 077.00464 999.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Tang
CEO | Chief Executive Officer | 57 | 31/12/12 |
Michael Hearne
DFI | Director of Finance/CFO | 61 | 31/12/14 |
Ryan Cole
COO | Chief Operating Officer | - | 31/12/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kevin Tang
CEO | Chief Executive Officer | 57 | 31/12/12 |
Craig Johnson
BRD | Director/Board Member | 62 | 30/06/17 |
Aaron Davis
BRD | Director/Board Member | 45 | 30/11/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/04/24 | 18,810 | +10.00% | 1 |
| 22/04/24 | 17,100 | -0.71% | 4 |
Delayed Quote OTC Markets, April 25, 2024 at 07:44 pm
More quotes
Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +25.40% | 53.42M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ODT Stock
